Johnson & Johnson (NYSE:JNJ) Shares Bought by Invesco Ltd.

Invesco Ltd. increased its stake in Johnson & Johnson (NYSE:JNJ) by 6.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 19,126,079 shares of the company’s stock after acquiring an additional 1,171,975 shares during the quarter. Johnson & Johnson makes up 0.5% of Invesco Ltd.’s holdings, making the stock its 16th largest holding. Invesco Ltd. owned about 0.79% of Johnson & Johnson worth $2,766,014,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of JNJ. IFS Advisors LLC raised its holdings in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after buying an additional 100 shares during the period. WealthTrak Capital Management LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in Johnson & Johnson during the 4th quarter valued at $29,000. Bay Harbor Wealth Management LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at $32,000. Finally, Conquis Financial LLC purchased a new position in Johnson & Johnson during the 4th quarter valued at about $33,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

JNJ has been the subject of several research reports. Wells Fargo & Company lowered their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Leerink Partners reduced their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Finally, Bank of America increased their price objective on Johnson & Johnson from $159.00 to $171.00 and gave the stock a “neutral” rating in a report on Wednesday, March 5th. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $171.33.

Johnson & Johnson Stock Down 4.3 %

Shares of JNJ opened at $153.03 on Monday. The business’s 50 day simple moving average is $159.75 and its 200-day simple moving average is $155.76. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a market capitalization of $368.77 billion, a P/E ratio of 23.01, a PEG ratio of 2.56 and a beta of 0.49. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter last year, the company posted $2.29 EPS. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.